Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Bojana B Beleslin ČokićDepartment for Sero and Molecular Diagnostics, Institute of Virology, Vaccines and Sera "Torlak", Vojvode Stepe 458, 11221 Belgrade, Serbia.
Sandra Bižić RadulovićClinic of Hematology, University Clinical Center of Serbia, Dr Koste Todorovića, 11000 Belgrade, Serbia.
Tijana SubotičkiDepartment of Molecular Oncology, Institute for Medical Research, National Institute of Republic of Serbia, University of Belgrade, Dr Subotića 4, 11129 Belgrade, Serbia.ORCID 0000-0002-5132-8319
Vladan P ČokićDepartment of Molecular Oncology, Institute for Medical Research, National Institute of Republic of Serbia, University of Belgrade, Dr Subotića 4, 11129 Belgrade, Serbia.ORCID 0000-0002-0362-1449
Constance T NoguchiMolecular Medicine Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Nebojša BojanićClinic for Urology, University Clinical Center of Serbia, Resavska 51, 11000 Belgrade, Serbia.ORCID 0000-0001-7616-507X
Svetozar DamjanovićClinic of Endocrinology, University Clinical Center of Serbia, Dr Subotića 13, 11000 Belgrade, Serbia.
Funding
Ministry of Education, Science and Technological Development of the Republic of Serbia 451-03-68/2022-14/200015 and 41009
6 · The paper itself
Abstract
Clear-cell renal cell carcinoma (ccRCC) is associated with the mutated von Hippel-Lindau (VHL) gene leading to the activation of hypoxia-inducible factor 1A (HIF1A) and subsequent overexpression of erythropoietin (EPO). We analyzed tumor and healthy tissues from 43 ccRCC patients after radical nephrectomy and cultured 786-O (biallelic
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Regulation of Erythropoietin Activity in Clear Renal Cell Carcinoma. · full record | OpenQuestion